All Scientific References

Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, and Walsh SL. 2017. Oral Cannabidiol Does Not Produce a Signal for Abuse Liability in Frequent Marijuana Smokers. Drug and Alcohol Dependence 172: 9-13.

Baron EP. 2018. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache 58(7): 1139-1186.

Bryda EC. 2013. The Mighty Mouse: The Impact of Rodents on Advances in Biomedical Research. Missouri Medicine 110(3): 207-211.

Campos AC, Fogaca MV, Scarante FF, Joca SRL, Sales AJ, Gomes FV, Sonego AB, Rodrigues NS, Galve-Roperh IG, and Guimaraes FS. 2017. Plastic and Neuroprotective Mechanisms Involved in Therapeutic Effects of Cannabidiol in Psychiatric Disorders. Frontiers in Pharmacology 8: 269.

Colizzi M and Bhattacharyya S. 2017. Does Cannabis Composition Matter? Differential Effects of Delta-9-Tetrahydrocannabinol and Cannabidiol on Human Cognition. Current Addiction Reports 4(2): 62-74.

Costa B, Trovato AE, Cornelli F, Giagnoni G, and Colleoni M. 2007. The Non-Psychoactive Cannabis Constituent Cannabidiol is an Orally Effective Therapeutic Agent in Rat Chronic Inflammatory and Neuropathic Pain. European Journal of Pharmacology 556(1-3): 75-83.

Davis MP. 2016. Cannabinoids for Symptom Management and Cancer Therapy: The Evidence. Journal of the National Comprehensive Cancer Network 14(7): 915-922.

Donvito G, Nass SR, Wilkerson JL, Curry ZA, Schurman LD, Kinsey SG, and Lichtman AH. 2018. The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology 43: 52-79.

Fasinu PS, Phillips S, ElSohly MA, and Walker LA. 2016. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents. Pharmacotherapy 36(7): 781-796.

Genaro K, Fabris D, Arantes ALF, Zuardi AW, Crippa JAS, and Prado WA. 2017. Cannabidiol is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats. Frontiers in Pharmacology 8: 391.

Gruden G, Barutta F, Kunos G, and Pacher P. 2016. Role of the Endocannabinoid System in Diabetes and Diabetic Complications. British Journal of Clinical Pharmacology 173(7): 1116-1127.

Gupta SC, Kunnumakkara AB, Aggarwal S, and Aggarwal BB. 2018. Inflammation, a Double-Edge Sword for Cancer and Other Age-Related Diseases. Frontiers in Immunology 9: 2160.

Hazekamp A, Tejkalova K, and Papadimitriou S. 2016. Cannabis: From Cultivar to Chemovar II-A Metabolomics Approach to Cannabis Classification. Cannabis and Cannabinoid Research 1(1): 202-215.

Hill KP, Palastro MD, Johnson B, and Ditre JW. 2017. Cannabis and Pain: A Clinical Review. Cannabis and Cannabinoid Research 2(1): 96-104.

Jadoon KA, Tan GD, and O'Sullivan SE. 2017. A Single Dose of Cannabidiol Reduces Blood Pressure in Healthy Volunteers in a Randomized Crossover Study. JCI Insight 2(12): e93760.

Lehmann C, Fisher NB, Tugwell B, Szczesniak A, Kelly M, and Zhou J. 2016. Experimental Cannabidiol Treatment Reduces Early Pancreatic Inflammation in Type 1 Diabetes. Clinical Hemorheology and Microcirculation 64(4): 655-662.

Ligresti A, Petrocellis LD, and Marzo VD. 2016. From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleitropic Physiological and Pathological Roles Through Complex Pharmacology. Physiological Reviews 96(4): 1593-1659.

Lu HC and Mackie K. 2016. An Introduction to the Endogenous Cannabinoid System. Biological Psychiatry 79(7): 516-525.

Luchicchi A and Pistis M. 2012. Anandamide and 2-Arachidonoylglycerol: Pharmacological Properties, Functional Features, and Emerging Specificities of the Two Major Endocannabinoids. Molecular Neurobiology 46(2): 374-392.

Maida V and Daeninck PJ. 2016. A User's Guide to Cannabinoid Therapies in Oncology. Current Oncology 23(6): 398-406.

Marzo VD and Piscitelli F. 2015. The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics 12(4): 692-698.

McCarty MF and DiNicolantonio JJ. 2016. Lauric Acid-Rich Medium-Chain Triglycerides Can Substitute For Other Oils in Cooking Applications and May Have Limited Pathogenicity. Open Heart 3(2): e000467.

Miller BR and Hen R. 2015. The Current State of the Neurogenic Theory of Depression and Anxiety. Current Opinion in Neurobiology 30: 51-58.

Mounessa JS, Siegel JA, Dunnick CA, and Dellavalle RP. 2017. The Role of Cannabinoids in Dermatology. Journal of the American Academy of Dermatology 77(1): 188-190.

Olah A, Toth BI, Borbiro I, Sugawara K, Szollosi AG, Czifra G, Pal B, Ambrus L, Kloepper J, Camera E, Ludovici M, Picardo M, Voets T, Zouboulis CC, Paus R, and Biro T. 2014. Cannabidiol Exerts Sebostatic and Antiinflammatory Effects on Human Sebocytes. The Journal of Clinical Investigation 124(9): 3713-3724.

O'Sullivan SE and Kendall DA. 2010. Cannabinoid Activation of Peroxisome Proliferator-Activated Receptors: Potential for Modulation of Inflammatory Disease. Immunobiology 215(8): 611-616.

Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, and Bifulco M. 2017. Cannabidiol: State of the Art and New Challenges for Therapeutic Applications. Pharmacology and Therapeutics 175: 133-150.

Poleg S, Golubchik P, Offen D, and Weizman A. 2019. Cannabidiol as a Suggested Candidate for Treatment of Autism Spectrum Disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 89: 90-96.

Ressler KJ and Nemeroff CB. 2000. Role of Serotonergic and Noradrenergic Systems in the Pathophysiology of Depression and Anxiety Disorders. Depression and Anxiety 12 Suppl 1: 2-19.

Rial SA, Karelis AD, Bergeron KF, and Mounier C. 2016. Gut Microbiota and Metabolic Health: The Potential Beneficial Effects of a Medium Chain Triglyceride Diet in Obese Individuals. Nutrients 8(5): E281.

Scharf EL. 2017. Translating Endocannabinoid Biology Into Clinical Practice: Cannabidiol for Stroke Prevention. Cannabis and Cannabinoid Research 2(1): 259-264.

Sharma A, Bemis M, and Desilets AR. 2014. Role of Medium Chain Triglycerides in the Treatment of Mild to Moderate Alzheimer's Disease. American Journal of Alzheimer's Disease & Other Dementias 29(5): 409-414.

Turgeman I and Bar-Sela G. 2017. Cannabis Use in Palliative Oncology: A Review of the Evidence for Popular Indications. Israel Medical Association Journal 19(2): 85-88.

Wang Y, Mukhopadhyay P, Cao Z, Wang H, Feng D, Hasko G, Mechoulam R, Gao B, and Pacher P. 2017. Cannabidiol Attenuates Alcohol-Induced Liver Steatosis, Metabolic Dysregulation, Inflammation, and Neutrophil-Mediated Injury. Scientific Reports 7: 12064.

Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S, and Gallily R. 2006. Cannabidiol Lowers Incidence of Diabetes in Non-Obese Diabetic Mice. Autoimmunity 39(2): 143-151.

Wrona O, Rafinska K, Mozenski C, and Buszewski B. 2017. Supercritical Fluid Extraction of Bioactive Compounds from Plant Materials. Journal of AOAC International 100(6): 1624-1635.

Yang JH, Yoon JY, Kwon HH, Min S, Moon J, and Suh DH. 2017. Seeking New Acne Treatment from Natural Products, Devices, and Synthetic Drug Discovery. Dermato-Endocrinology 9(1): eCollection.

Zehra A, Burns J, Liu CK, Manza P, Wiers CE, Volkow ND, and Wang GJ. 2018. Cannabis Addiction and the Brain: a Review.. Journal of Neuroimmune Pharmacology 13(4): 438-452.

Zendulka O, Dovrtelova G, Noskova K, Turjap M, Sulcova A, Hanus L, and Jurica J. 2016. Cannabinoids and Cytochrome P450 Interactions. Current Drug Metabolism 17(3): 206-226.

Zlebnik NE and Cheer JF. 2016. Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?. Annual Review of Neuroscience 39: 1-17.